ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors

In the ATLAS-A/B trial, prophylactic treatment with fitusiran resulted in significant reductions in annualized bleeding rates compared with on-demand factor replacement therapy in patients with hemophilia A or B and no inhibitors.